Skip to Main Content

Insys Therapeutics, a once high-flying drug maker, has agreed to pay $225 million to settle criminal and civil investigations into marketing practices of using kickbacks to persuade doctors to prescribe its Subsys painkiller, which contains fentanyl, a powerful and addictive opioid.

As part of the deal, an Insys subsidiary will plead guilty to five counts of mail fraud, while the company will pay a $2 million fine, $28 million in forfeitures, and $195 million to settle charges of violating the federal False Claims Act, which involves defrauding the federal government through sales to health care programs such as Medicare. The company must also sell the painkiller within a year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED